drugset / Trial / NCT05311514

Allogeneic Platelet Lysate Eye Drops for the Treatment of Severe Chronic Ocular Graft-versus-host Disease

NCT05311514

Phase 2 Completed 38 enrolled St. Petersburg State Pavlov Medical University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study evaluates the efficacy and safety of allogeneic platelet lysate eye drops in patients with severe ocular graft versus host disease refractory to conventional systemic and local treatments. The corneal staining, conjunctival hyperemia, tear film break up time,Schirmer test and ocular surface disease index will be evaluated before and after allogeneic platelet lysate treatment. The safety of allogeneic platelet lysate treatment will be also assessed.

Timeline

Start
2021-04-01
Primary completion
2024-11-29
Completion
2024-11-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Platelet Lysate Unknown 20 % Other
Subject Platelet Lysate Unknown 50 % Other